This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Dec 2010

LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients

New data to be presented show that afatinib (BIBW 2992) leads to a significant four-fold extension in progression-free survival for lung cancer patients most likely to have an epidermal growth factor receptor (EGFR) mutation.

Related News